Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone

NCT03616834 is registered in ClinicalTrials.gov with Effector Therapeutics as lead sponsor.

NCT NCT03616834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03616834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Lead sponsor
Effector Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
July 25, 2018
Completion date
June 30, 2021
Enrollment
39 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors